Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II olaparib maintenance after docetaxel in metastatic castration-resistant prostate cancer
2017-001469-26Phase 2Active
- Sponsor
- SOGUG
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of olaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SOGUG. Primary endpoint: Radiographic progression-free survival. Started Oct 2017; status: active.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2017-001469-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001469-26.